|
gptkbp:instanceOf
|
gptkb:antidepressant
gptkb:drug
|
|
gptkbp:abbreviation
|
gptkb:VEN
|
|
gptkbp:approvedBy
|
1993
|
|
gptkbp:ATCCode
|
gptkb:N06AX16
|
|
gptkbp:brand
|
gptkb:Effexor_XR
gptkb:Effexor
|
|
gptkbp:CASNumber
|
93413-69-5
|
|
gptkbp:contraindication
|
gptkb:MAO_inhibitors
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:drugClass
|
gptkb:norepinephrine_reuptake_inhibitor
|
|
gptkbp:eliminationHalfLife
|
5 hours
11 hours (active metabolite)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
extended-release tablet
extended-release capsule
immediate-release tablet
|
|
gptkbp:hasMolecularFormula
|
C17H27NO2
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
weak inhibitor of dopamine reuptake
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
277.403 g/mol
|
|
gptkbp:patentExpired
|
2008
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
5656
5454
|
|
gptkbp:relatedTo
|
gptkb:desvenlafaxine
gptkb:levomilnacipran
gptkb:milnacipran
gptkb:duloxetine
|
|
gptkbp:riskFactor
|
gptkb:discontinuation_syndrome
gptkb:serotonin_syndrome
hypertension
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:sexual_dysfunction
nausea
dizziness
headache
sweating
insomnia
dry mouth
increased blood pressure
|
|
gptkbp:UNII
|
O7G3K8V52I
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Venlafaxine
|